» Articles » PMID: 35530025

Effect of Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs

Abstract

In the last decade, the market for new psychoactive substances has been enriched by numerous psychedelic phenethylamines, which mimic the psychoactive effect of lysergic acid diethylamide (LSD). In particular, the -NBOMe series, which are more potent than their 2C compounds analogs, are considered worthy substitutes for LSD by users. The purpose of this study was to assess the effects of 25-NBOMe and its halogenated derivatives (25-NBOMe and 25-NBOMe) in comparison to their 2C compounds analogs and LSD on the sensorimotor (visual, acoustic, and overall tactile), reaction time, spontaneous (total distance traveled) and stimulated (drag, accelerod test) motor activity, grip strength test, and prepulse inhibition (PPI) responses in mice. Systemic administration of -NBOMe, 2C compounds analogs, and LSD (0.001-10 mg/kg) differently impaired the sensorimotor, reaction time, motor, and PPI responses in mice. In particular, halogenated (25I and 25B)-NBOMe derivatives appear to be more effective than the entire class of 2C compounds analogs in altering visual and acoustic responses, affecting reaction time, and motor and sensory gating in PPI test. In fact, the specific rank order of compounds potency for nearly all of the experiments showed that (25I and 25B)-NBOMe were more potent than 2C compounds analogs and LSD. -NBOMe and 2C compounds analogs impaired not only the reception of incoming sensory stimuli (visual and acoustic), but their correct brain processing (PPI) in an equal and sometimes stronger way than LSD. This sensory impairment directly affected the spontaneous motor response and reaction time of mice, with no change in performance in stimulated motor activity tests. These aspects should be carefully considered to better understand the potential danger that psychedelic phenethylamines, in particular -NBOMe, may pose to public health, with particular reference to decreased performance in driving and hazardous works that require special sensorimotor skills.

Citing Articles

Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?.

Gil-Martins E, Barbosa D, Borges F, Remiao F, Silva R Toxicol Rep. 2025; 14:101890.

PMID: 39867514 PMC: 11762925. DOI: 10.1016/j.toxrep.2025.101890.


Pharmaco-toxicological effects of the novel tryptamine hallucinogen 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice-from a human poisoning case to the preclinical evidence.

Bassi M, Bilel S, Tirri M, Corli G, Di Rosa F, Gregori A Psychopharmacology (Berl). 2024; 241(3):489-511.

PMID: 38214743 PMC: 10884077. DOI: 10.1007/s00213-024-06526-8.


Molecular and Medical Aspects of Psychedelics.

Wojtas A, Golembiowska K Int J Mol Sci. 2024; 25(1).

PMID: 38203411 PMC: 10778977. DOI: 10.3390/ijms25010241.


Pharmaco-Toxicological Effects of Atypical Synthetic Cathinone Mephtetramine (MTTA) in Mice: Possible Reasons for Its Brief Appearance over NPSs Scene.

Corli G, Tirri M, Arfe R, Marchetti B, Bernardi T, Borsari M Brain Sci. 2023; 13(2).

PMID: 36831704 PMC: 9954072. DOI: 10.3390/brainsci13020161.


Behavioral and Pharmacokinetics Studies of -Methyl-2-Aminoindane (NM2AI) in Mice: An Aminoindane Briefly Used in the Illicit Drug Market.

Tirri M, Corli G, Arfe R, Marchetti B, Bilel S, Bernardi T Int J Mol Sci. 2023; 24(3).

PMID: 36768197 PMC: 9916073. DOI: 10.3390/ijms24031882.

References
1.
Ossato A, Vigolo A, Trapella C, Seri C, Rimondo C, Serpelloni G . JWH-018 impairs sensorimotor functions in mice. Neuroscience. 2015; 300:174-88. DOI: 10.1016/j.neuroscience.2015.05.021. View

2.
Simmler L, Buser T, Donzelli M, Schramm Y, Dieu L, Huwyler J . Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2012; 168(2):458-70. PMC: 3572571. DOI: 10.1111/j.1476-5381.2012.02145.x. View

3.
ANDEN N, CORRODI H, Fuxe K, Meek J . Hallucinogenic phenylethylamines: interactions with serotonin turnover and receptors. Eur J Pharmacol. 1974; 25(2):176-84. DOI: 10.1016/0014-2999(74)90047-8. View

4.
Elmore J, Decker A, Sulima A, Rice K, Partilla J, Blough B . Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology. 2018; 142:240-250. PMC: 6119551. DOI: 10.1016/j.neuropharm.2018.02.033. View

5.
Brandt S, Kavanagh P, Twamley B, Westphal F, Elliott S, Wallach J . Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Test Anal. 2017; 10(2):310-322. PMC: 6230476. DOI: 10.1002/dta.2222. View